Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cardio Diagnostics Holdings, Inc. (CDIO)
USD1.79
-0.01 (-0.56%)
US NASDAQ Healthcare Biotechnology
Address
400 N Aberdeen St 60642
Chicago, IL, US
Chicago, IL, US
CEO
Meeshanthini V. Dogan
Website
cardiodiagnosticsinc.com
IPO
2022-01-14
CIK 1870144 ISIN US14159C2026
Also trades on
NASDAQ Capital Market · CDIO (USD)
NASDAQ Global Market · CDIOW (USD)
NASDAQ Global Market · MAAQ (USD)
NASDAQ Global Market · MAAQR (USD)
NASDAQ Global Market · MAAQU (USD)
NASDAQ Global Market · MAAQW (USD)
Description
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.79
-0.01 (-0.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
65.8K
Beta
2.20
Float Shares
1.73M
Free Float %
93.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.74% | -11.93% | -22.89% | +30.25% | -48.16% | -42.80% | -64.93% | -96.51% | -99.47% | -99.47% | -99.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.79
DCF (Unlevered)
2.29
+27.8%
DCF (Levered)
2.00
+11.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-3.33
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-57.5% Q1'26: +185.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+60.1% ★ Q1'26: +35.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-40,641.5% Q1'26: -58,357.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-43,737.5% Q1'26: -66,598.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-253.5% Q1'26: -325.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-93.5% ★ Q1'26: +68.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.11× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
950.00
est: 500.0K (-99.8%)
|
17.1K
est: 39.1K (-56.4%)
|
34.9K
est: 55.0K (-36.6%)
|
14.8K
est: 525.0K (-97.2%)
|
25.00M
25.00M – 25.00M
+4,661.9% YoY
|
| EBITDA |
-4.64M
est: -300.0K (-1,448.3%)
|
-1.53M
est: -39.1K (-3,809.8%)
|
-8.09M
est: -55.0K (-14,606.3%)
|
-6.09M
est: -525.0K (-1,059.2%)
|
-25.00M
-25.00M – -25.00M
-4,661.9% YoY
|
| EBIT |
-4.66M
est: -300.0K (-1,453.7%)
|
-1.64M
est: -39.1K (-4,095.0%)
|
-8.36M
est: -55.0K (-15,108.8%)
|
-6.48M
est: -525.0K (-1,135.1%)
|
-25.00M
-25.00M – -25.00M
-4,661.9% YoY
|
| Net Income |
-4.66M
est: -701.91M (+99.3%)
|
-8.38M
est: -823.5K (-917.2%)
|
-8.38M
est: -18.92M (+55.7%)
|
-6.50M
est: -12.08M (+46.2%)
|
-28.90M
-28.90M – -28.90M
-139.1% YoY
|
| SGA |
4.49M
est: 602.25M (-99.3%)
|
7.10M
est: 47.54M (-85.1%)
|
8.35M
est: 66.81M (-87.5%)
|
766.9K
est: 637.69M (-99.9%)
|
30.37B
30.37B – 30.37B
+4,661.9% YoY
|
| EPS |
-45.30
est: -26.10 (-73.6%)
|
-19.80
est: -0.47 (-4,111.1%)
|
-9.30
est: -10.80 (+13.9%)
|
-3.71
est: -6.90 (+46.2%)
|
-16.50
-16.50 – -16.50
-139.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.25M
OE per share TTM
-3.21
Owner's Yield
-141.84%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4,680.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 1.07M | 5.20% | 1.07M | — | 1.07M | — | HC | Delaware | 2024-02-02 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADVISOR GROUP HOLDINGS, INC. | — -3.7K (-100.0%) | — -3.4K (-100.0%) | 0.00% -0.219 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 36.1K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
12.8K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+12,820
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 3,205 | 1.95 | 6.2K | 10,464 | D | ↗ |
| 2026-03-31 | Fung Peter K | Director | A-Award | A | Stock Options (Right to Buy) | 3,205 | 1.95 | 6.2K | 9,513 | D | ↗ |
| 2026-03-31 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 3,205 | 1.95 | 6.2K | 10,464 | D | ↗ |
| 2026-03-31 | Betts Wendy J | Director | A-Award | A | Stock Options (Right to Buy) | 3,205 | 1.95 | 6.2K | 9,513 | D | ↗ |
| 2025-12-31 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 2,306 | 2.71 | 6.2K | 7,259 | D | ↗ |
| 2025-12-31 | Fung Peter K | Director | A-Award | A | Stock Options (Right to Buy) | 2,306 | 2.71 | 6.2K | 6,308 | D | ↗ |
| 2025-12-31 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 2,306 | 2.71 | 6.2K | 7,259 | D | ↗ |
| 2025-12-31 | Betts Wendy J | Director | A-Award | A | Stock Options (Right to Buy) | 2,306 | 2.71 | 6.2K | 6,308 | D | ↗ |
| 2025-09-30 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 1,559 | 4.01 | 6.3K | 4,953 | D | ↗ |
| 2025-09-30 | Fung Peter K | Director | A-Award | A | Stock Options (Right to Buy) | 1,559 | 4.01 | 6.3K | 4,002 | D | ↗ |
| 2025-09-30 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 1,559 | 4.01 | 6.3K | 4,953 | D | ↗ |
| 2025-09-30 | Betts Wendy J | Director | A-Award | A | Stock Options (Right to Buy) | 1,559 | 4.01 | 6.3K | 4,002 | D | ↗ |
| 2025-06-30 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 1,736 | 3.60 | 6.2K | 3,394 | D | ↗ |
| 2025-06-30 | Fung Peter K | Director | A-Award | A | Stock Options (Right to Buy) | 1,736 | 3.60 | 6.2K | 2,443 | D | ↗ |
| 2025-06-30 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 1,736 | 3.60 | 6.2K | 3,394 | D | ↗ |
| 2025-06-30 | Betts Wendy J | Director | A-Award | A | Stock Options (Right to Buy) | 1,736 | 3.60 | 6.2K | 2,443 | D | ↗ |
| 2025-03-31 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 18,939 | 0.33 | 6.2K | 49,744 | D | ↗ |
| 2025-03-31 | Fung Peter K | Director | A-Award | A | Stock Options (Right to Buy) | 18,939 | 0.33 | 6.2K | 21,211 | D | ↗ |
| 2025-03-31 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 18,939 | 0.33 | 6.2K | 49,744 | D | ↗ |
| 2025-03-31 | Betts Wendy J | Director | A-Award | A | Stock Options (Right to Buy) | 18,939 | 0.33 | 6.2K | 21,211 | D | ↗ |
| 2024-12-31 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 4,544 | 0.92 | 4.2K | 30,805 | D | ↗ |
| 2024-12-31 | Fung Peter K | Director | — | — | Stock Options (Right to Buy) | 2,272 | 0.92 | 2.1K | 0 | D | ↗ |
| 2024-12-31 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 4,544 | 0.92 | 4.2K | 30,805 | D | ↗ |
| 2024-12-31 | Betts Wendy J | Director | — | — | Stock Options (Right to Buy) | 2,272 | 0.92 | 2.1K | 0 | D | ↗ |
| 2024-09-30 | Levy Oded | Director | A-Award | A | Stock Options (Right to Buy) | 18,686 | 0.22 | 4.1K | 26,261 | D | ↗ |
| 2024-09-30 | Lau Stanley K. | Director | A-Award | A | Stock Options (Right to Buy) | 18,686 | 0.22 | 4.1K | 26,261 | D | ↗ |
| 2024-09-30 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 18,686 | 0.22 | 4.1K | 26,261 | D | ↗ |
| 2024-09-30 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 18,686 | 0.22 | 4.1K | 26,261 | D | ↗ |
| 2024-09-06 | Philibert Robert | Director / Officer | P-Purchase | A | Common Stock | 7,460 | 0.28 | 2.1K | 1,683,867 | — | ↗ |
| 2024-09-06 | Dogan Timur | Officer | P-Purchase | A | Common Stock | 68,965 | 0.29 | 20.0K | 197,310 | D | ↗ |
| 2024-09-06 | Dogan Meeshanthini | Director / Officer | P-Purchase | A | Common Stock | 68,965 | 0.29 | 20.0K | 1,683,867 | — | ↗ |
| 2024-06-30 | Levy Oded | Director | A-Award | A | Stock Options (Right to Buy) | 7,575 | 0.55 | 4.2K | 7,575 | — | ↗ |
| 2024-06-30 | Lau Stanley K. | Director | A-Award | A | Stock Options (Right to Buy) | 7,575 | 0.55 | 4.2K | 7,575 | — | ↗ |
| 2024-06-30 | Intrater James | Director | A-Award | A | Stock Options (Right to Buy) | 7,575 | 0.55 | 4.2K | 7,575 | — | ↗ |
| 2024-06-30 | Burton Paul Frederick | Director | A-Award | A | Stock Options (Right to Buy) | 7,575 | 0.55 | 4.2K | 7,575 | — | ↗ |
| 2024-03-31 | Levy Oded | Director | M-Exempt | A | Common Stock | 8,803 | 1.42 | 12.5K | 71,596 | — | ↗ |
| 2024-03-31 | Lau Stanley K. | Director | M-Exempt | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-31 | Intrater James | Director | M-Exempt | A | Common Stock | 8,803 | 1.42 | 12.5K | 71,596 | — | ↗ |
| 2024-03-31 | Burton Paul Frederick | Director | M-Exempt | A | Common Stock | 8,803 | 1.42 | 12.5K | 8,803 | — | ↗ |
| 2024-01-31 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 917 | 2.18 | 2.0K | 91,522 | — | ↗ |
| 2024-01-23 | Philibert Robert | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 142,876 | 2.11 | 301.5K | 805,465 | — | ↗ |
| 2024-01-23 | Luqman Elisa V | Officer | A-Award | A | Stock Options (Right to Buy) | 35,719 | 2.11 | 75.4K | 264,832 | — | ↗ |
| 2024-01-23 | Levy Oded | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-23 | Lau Stanley K. | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-23 | Intrater James | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-23 | Hosseinion Warren | Director | A-Award | A | Stock Options (Right to Buy) | 35,719 | 2.11 | 75.4K | 502,195 | — | ↗ |
| 2024-01-23 | Dogan Timur | Officer | A-Award | A | Stock Options (Right to Buy) | 476,256 | 2.11 | 1.00M | 1,433,958 | — | ↗ |
| 2024-01-23 | Dogan Meeshanthini | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 476,256 | 2.11 | 1.00M | 1,433,958 | — | ↗ |
| 2024-01-23 | Burton Paul Frederick | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-23 | Abdullahi Khullani | Officer | A-Award | A | Stock Options (Right to Buy) | 238,128 | 2.11 | 502.5K | 304,128 | — | ↗ |
| 2023-12-31 | Sim Brandon | Director | M-Exempt | D | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Levy Oded | Director | P-Purchase | D | Restricted Stock Units | 0 | 0.00 | — | 0 | D | ↗ |
| 2023-12-31 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 5,020 | 2.49 | 12.5K | 90,605 | — | ↗ |
| 2023-12-31 | Intrater James | Director | M-Exempt | D | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-18 | Burton Paul Frederick | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-31 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 6,631 | 0.30 | 2.0K | 83,979 | — | ↗ |
| 2023-09-30 | Sim Brandon | Director | M-Exempt | A | Common Stock | 36,765 | 0.34 | 12.5K | 57,773 | D | ↗ |
| 2023-09-30 | Levy Oded | Director | P-Purchase | D | Restricted Stock Units | 0 | 0.00 | — | 0 | D | ↗ |
| 2023-09-30 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 36,765 | 0.34 | 12.5K | 77,348 | — | ↗ |
| 2023-09-30 | Intrater James | Director | M-Exempt | A | Common Stock | 36,765 | 0.34 | 12.5K | 57,773 | D | ↗ |
| 2023-08-31 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 3,637 | 0.55 | 2.0K | 34,701 | — | ↗ |
| 2023-08-31 | Dogan Timur | Officer | P-Purchase | A | Common Stock | 16,481 | 0.55 | 9.0K | 128,345 | — | ↗ |
| 2023-08-31 | Dogan Meeshanthini | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 16,481 | 0.55 | 9.0K | 128,345 | — | ↗ |
| 2023-08-28 | Philibert Robert | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 17,900 | 0.60 | 10.7K | 1,649,692 | — | ↗ |
| 2023-08-25 | Dogan Timur | Officer | P-Purchase | A | Common Stock | 1,770 | 0.56 | 982.35 | 111,864 | — | ↗ |
| 2023-08-25 | Dogan Meeshanthini | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,770 | 0.56 | 982.35 | 111,864 | — | ↗ |
| 2023-08-24 | Philibert Robert | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 16,000 | 0.60 | 9.6K | 1,631,792 | — | ↗ |
| 2023-07-31 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 1,653 | 1.21 | 2.0K | 31,064 | — | ↗ |
| 2023-07-01 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 8,403 | 1.19 | 10.0K | 29,411 | — | ↗ |
| 2023-06-30 | Sim Brandon | Director | M-Exempt | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-30 | Levy Oded | Director | M-Exempt | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-30 | Lau Stanley K. | Director | M-Exempt | A | Common Stock | 21,008 | 1.19 | 25.0K | 21,008 | — | ↗ |
| 2023-06-30 | Intrater James | Director | M-Exempt | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-23 | Philibert Robert | Director / Officer / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 148,500 | 1.26 | 187.1K | 148,500 | — | ↗ |
| 2023-06-23 | Luqman Elisa V | Officer | A-Award | A | Stock Options (Right to Buy) | 57,750 | 1.26 | 72.8K | 57,750 | — | ↗ |
| 2023-06-23 | Hosseinion Warren | Director | A-Award | A | Stock Options (Right to Buy) | 123,750 | 1.26 | 155.9K | 123,750 | — | ↗ |
| 2023-06-23 | Dogan Timur | Officer | A-Award | A | Stock Options (Right to Buy) | 272,250 | 1.26 | 343.0K | 272,250 | I | ↗ |
| 2023-06-23 | Dogan Meeshanthini | Director / Officer / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 272,250 | 1.26 | 343.0K | 272,250 | D | ↗ |
| 2023-06-23 | Abdullahi Khullani | Officer | A-Award | A | Stock Options (Right to Buy) | 66,000 | 1.26 | 83.2K | 66,000 | — | ↗ |
| 2023-06-19 | Sim Brandon | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-19 | Levy Oded | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-19 | Lau Stanley K. | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-19 | Intrater James | Director | A-Award | A | Restricted Stock Units | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-25 | Sim Brandon | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-25 | Philibert Robert | Officer | — | I | Common Stock | 0 | 0.00 | — | 7,601 | — | ↗ |
| 2022-10-25 | Mana Capital LLC | Director | J-Other | D | Private Warrant | 2,500,000 | 0.00 | — | 0 | — | ↗ |
| 2022-10-25 | Luqman Elisa V | Officer | — | D | Stock Options (right to buy) | 171,363 | 3.90 | 668.3K | — | — | ↗ |
| 2022-10-25 | Levy Oded | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-10-25 | Lau Stanley K. | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-10-25 | Intrater James | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-10-25 | Hosseinion Warren | Director | — | D | Stock Options (right to buy) | 342,726 | 3.90 | 1.34M | — | — | ↗ |
| 2022-10-25 | Dogan Timur | Officer | — | I | Stock Options (right to buy) | 685,452 | 3.90 | 2.67M | — | — | ↗ |
| 2022-10-25 | Dogan Meeshanthini | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,586,464 | — | ↗ |
| 2022-10-25 | Abdullahi Khullani | Officer | — | D | Common Stock | 0 | 0.00 | — | 14,554 | — | ↗ |
| 2021-11-30 | Mana Capital LLC | 10% Owner | J-Other | A | Common Stock, par value $0.00001 per share | 75,000 | 0.00 | — | 1,565,000 | — | ↗ |
| 2021-11-22 | Mortman Loren | Director | — | D | Common Stock, par value $0.00001 per share | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2021-11-22 | Mana Capital LLC | 10% Owner | — | D | Common Stock, par value $0.00001 per share | 0 | 0.00 | — | 1,490,000 | — | ↗ |
| 2021-11-22 | LIU ALLAN | Director | — | D | Common Stock, par value $0.00001 per share | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2021-11-22 | Intrater Jonathan | Officer | — | D | Common Stock, par value $0.00001 per share | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.0K
Shares Outstanding
1.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Meeshanthini V. Dogan, CEO | 300.0K | — | — | 1.00M | — | 11.0K | 1.32M | 76.36% | ↗ |
| 2 | 2024 | Timur Dogan, CTO | 250.0K | — | — | 502.3K | — | 9.2K | 761.5K | 65.97% | ↗ |
| 3 | 2024 | Warren Hosseinion, Chairman | 300.0K | — | — | 75.3K | — | — | 375.3K | 20.07% | ↗ |
| 4 | 2024 | Elisa Luqman, CFO | 275.0K | — | — | 75.3K | — | — | 350.3K | 21.51% | ↗ |
| 5 | 2023 | Meeshanthini V. Dogan, CEO | 300.0K | — | — | 341.6K | — | 7.3K | 648.9K | 52.65% | ↗ |
| 6 | 2023 | Warren Hosseinion, Chairman | 300.0K | — | — | 155.3K | — | — | 455.3K | 34.11% | ↗ |
| 7 | 2023 | Timur Dogan, CTO | 250.0K | — | — | 196.7K | — | — | 446.7K | 44.03% | ↗ |
| 8 | 2023 | Elisa Luqman, CFO | 275.0K | — | — | 72.5K | — | — | 347.5K | 20.86% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Meeshanthini Dogan | Co-Founder, Chief Executive Officer & Director | 312.3K | — |
| Elisa Michael Luqman | Chief Financial Officer & Principal Accounting Officer | 275.0K | female |
| Timur Dogan | Chief Technology Officer | 260.3K | male |
| Robert A. Philibert | Co-Founder, Chief Medical Officer & Director | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CDIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
